Commercial orbital laboratories could extend proven microgravity research, but regulation and return logistics remain unresolved.

Merck’s MRK strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical ...

AstraZeneca AZN and MerckMRK are leading global drugmakers with broad and diversified portfolios. Merck is based in the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and ...

Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) has issued a positive opinion recommending approval of a combination of its ...

Drugmaker Merck is testing its antibody-drug conjugates (ADCs) alone and with its signature immunotherapy drug Keytruda ...

Merck’s MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company’s total ...

While an ovarian cancer trial of the Keytruda-Lynparza combination met its primary endpoint, Merck said that the role of Keytruda in the indication "remains uncertain at this time." (Merck & Co.) ...

Merck will share the ovarian cancer results at an upcoming medical meeting and with regulatory authorities worldwide, the company said. (iStock / Getty Images Plus) Merck’s Keytruda, with more than 40 ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...